Skip to content
Screener

Corcept Therapeutics CORT Total costs & expenses

Total costs & expenses at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$86.93M+29.6%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$151.11M+35.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$49.92M-9.2%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$40.01M+341%

Other financials

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Cash & equivalents$112.3M+9.3%
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation

See full
Market cap$11.67B+57.0%
Enterprise value$11.57B+57.7%
P/E211.5×+156×
P/S14.1×+3.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050613
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales4,0613,4336,9445,836
Research and development53,89060,471120,155121,206
Selling, general and administrative156,896103,851302,252194,511
Total operating expenses214,847167,755429,351321,553
Income (loss) from operations41,30026,675(8,301)30,091
Interest and other income4,6315,0179,51711,219
Income before income taxes45,93131,6921,21641,310
Income tax (expense) benefit(2,944)3,45710,01014,386

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Corcept Therapeutics's total costs & expenses?
Corcept Therapeutics (CORT) reported total costs & expenses of $214.85M in Q2 2026.
How has Corcept Therapeutics's total costs & expenses changed year-over-year?
Corcept Therapeutics's total costs & expenses increased by 28.1% year-over-year, from $167.76M to $214.85M.
What is the long-term trend for Corcept Therapeutics's total costs & expenses?
Over 4 years (2021 to 2025), Corcept Therapeutics's total costs & expenses has grown at a 31.2% compound annual growth rate (CAGR), from $241.5M to $716.61M.
What does total costs & expenses mean?
The aggregate of all operating and non-operating costs incurred by the company during a reporting period. This figure represents the total outflow of resources required to maintain business operations and support growth initiatives.

Ask your AI about Corcept Therapeutics's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude